199 related articles for article (PubMed ID: 36473821)
1. Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy.
Leemaqz SY; Kyinn M; Banks K; Sarkodie E; Goldstein D; Irwig MS
J Clin Lipidol; 2023; 17(1):103-111. PubMed ID: 36473821
[TBL] [Abstract][Full Text] [Related]
2. Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy.
Kyinn M; Banks K; Leemaqz SY; Sarkodie E; Goldstein D; Irwig MS
Int J Obes (Lond); 2021 Dec; 45(12):2562-2569. PubMed ID: 34400797
[TBL] [Abstract][Full Text] [Related]
3. Headache prevalence in transgender and gender diverse youth: A single-center case-control study.
Hranilovich JA; Millington K
Headache; 2023 Apr; 63(4):517-522. PubMed ID: 36988085
[TBL] [Abstract][Full Text] [Related]
4. Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis.
Gosiker B; Moutchia J; Nguyen N; Getahun D; Goodman M
J Clin Transl Endocrinol; 2024 Jun; 36():100349. PubMed ID: 38737626
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy.
Hashemi L; Zhang Q; Getahun D; Jasuja GK; McCracken C; Pisegna J; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M
J Sex Med; 2021 Sep; 18(9):1662-1675. PubMed ID: 34366264
[TBL] [Abstract][Full Text] [Related]
6. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI).
Cocchetti C; Castellini G; Iacuaniello D; Romani A; Maggi M; Vignozzi L; Schreiner T; den Heijer M; T'Sjoen G; Fisher AD
J Sex Med; 2021 Apr; 18(4):821-829. PubMed ID: 33745831
[TBL] [Abstract][Full Text] [Related]
7. Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents.
Millington K; Lee JY; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
Pediatrics; 2024 May; 153(5):. PubMed ID: 38567424
[TBL] [Abstract][Full Text] [Related]
8. Lipid profile and risk of cardiovascular disease in adult transgender men receiving cross-sex hormone therapy: a systematic review.
Quintela-Castro FCA; Pereira TSS; Alves DB; Chiepe L; Nascimento LS; Chiepe KCMB; Barcelos RM; Costa BM; Enriquez-Martinez OG; Rossoni JV; Bellettini-Santos T
Nutr Rev; 2023 Sep; 81(10):1310-1320. PubMed ID: 36779324
[TBL] [Abstract][Full Text] [Related]
9. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
Muir CA; Guttman-Jones M; Man EJ
Endocrine; 2024 Feb; ():. PubMed ID: 38386168
[TBL] [Abstract][Full Text] [Related]
10. Changes in depression symptom profile with gender-affirming hormone use in transgender persons.
Morssinkhof MWL; Wiepjes CM; van den Heuvel OA; Kreukels BPC; van der Tuuk K; T'Sjoen G; den Heijer M; Broekman BFP
J Affect Disord; 2024 Mar; 348():323-332. PubMed ID: 38154588
[TBL] [Abstract][Full Text] [Related]
11. The effect of testosterone on ovulatory function in transmasculine individuals.
Taub RL; Ellis SA; Neal-Perry G; Magaret AS; Prager SW; Micks EA
Am J Obstet Gynecol; 2020 Aug; 223(2):229.e1-229.e8. PubMed ID: 32044312
[TBL] [Abstract][Full Text] [Related]
12. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Gender-Affirming Medical Care on the Vaginal and Neovaginal Microbiomes of Transgender and Gender-Diverse People.
Krakowsky Y; Potter E; Hallarn J; Monari B; Wilcox H; Bauer G; Ravel J; Prodger JL
Front Cell Infect Microbiol; 2021; 11():769950. PubMed ID: 35127550
[TBL] [Abstract][Full Text] [Related]
14. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis.
Turino Miranda K; Kalenga CZ; Saad N; Dumanski SM; Collister D; Rytz CL; Lorenzetti DL; Chang DH; McClurg C; Sola DY; Ahmed SB
Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H861-H868. PubMed ID: 36053748
[TBL] [Abstract][Full Text] [Related]
15. Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults.
Roberts CM; Klein DA; Adirim TA; Schvey NA; Hisle-Gorman E
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3937-e3943. PubMed ID: 35452119
[TBL] [Abstract][Full Text] [Related]
16. HIV prevalence among transmasculine individuals at a New York City Community Health Centre: a cross-sectional study.
Radix AE; Larson EL; Harris AB; Chiasson MA
J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25981. PubMed ID: 36225145
[TBL] [Abstract][Full Text] [Related]
17. Expected vs. perceived effects of gender-affirming hormone therapy among transmasculine adolescents.
Taillefer V; Kelley J; Marsolais S; Chiniara L; Chadi N
J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1072-1078. PubMed ID: 37747085
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Gender Minority Stress and Resilience Among Transmasculine, Transfeminine, and Nonbinary Adolescents and Young Adults.
Poquiz JL; Coyne CA; Garofalo R; Chen D
J Adolesc Health; 2021 Mar; 68(3):615-618. PubMed ID: 33046360
[TBL] [Abstract][Full Text] [Related]
19. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
